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Abstract
Introduction: We sought to determine whether higher levels of the novel biomarker growth differentiation factor-
15 (GDF-15) are associated with poor outcomes and the presence of pulmonary vascular dysfunction (PVD) in
patients with acute respiratory distress syndrome (ARDS).
Methods: We conducted a retrospective cohort study in patients enrolled in the Acute Respiratory Distress
Syndrome Network Fluid and Catheter Treatment (FACT) Trial. Patients enrolled in the FACT Trial who received a
pulmonary artery catheter (PAC), had plasma available from the same study day and sufficient hemodynamic data
to determine the presence of PVD were included. Logistic regression was used to determine the association
between GDF-15 level and 60-day mortality.
Results: Of the 513 patients enrolled in the FACT Trial assigned to receive a PAC, 400 were included in this
analysis. Mortality at 60 days was significantly higher in patients whose GDF-15 levels were in the third (28%) or
fourth (49%) quartile when compared to patients with GDF-15 levels in the first quartile (12%) (P <0.001). Adjusting
for severity of illness measured by APACHE III score, the odds of death for patients with GDF-15 levels in the fourth
quartile when compared to the first quartile was 4.26 (95% CI 2.18, 10.92, P <0.001). When added to APACHE III
alone for prediction of 60-day mortality, GDF-15 levels increased the area under the receiver operating
characteristic curve from 0.72 to 0.77. At an optimal cutoff of 8,103 pg/mL, the sensitivity and specificity of GDF-15
for predicting 60-day mortality were 62% (95% CI 53%, 71%) and 76% (95% CI 71%, 81%), respectively. Levels of
GDF-15 were not useful in identifying the presence of PVD, as defined by hemodynamic measurements obtained
by a PAC.
Conclusions: In patients with ARDS, higher levels of GDF-15 are significantly associated with poor outcome but
not PVD.
Keywords: Acute respiratory distress syndrome, pulmonary vascular dysfunction, risk prediction, growth
differentiation factor-15
Introduction
Growth differentiation factor-15 (GDF-15) is a stress-
responsive cytokine and member of the transforming
growth factor-beta superfamily [1]. GDF-15 has been
extensively studied as a biomarker for cardiovascular
disease and was initially described as a marker of poor
outcomes in acute coronary syndromes and chronic
left-sided heart failure [2-8]. More recently, GDF-15
expression has shown promise as a biomarker for the
identification of and prognosis in pulmonary vascular
disorders including pulmonary embolism, idiopathic
pulmonary arterial hypertension (PAH), and PAH asso-
ciated with systemic sclerosis [9,10].
Acute respiratory distress syndrome (ARDS) is a devas-
tating cause of respiratory failure that is commonly
accompanied by pulmonary vascular and right ventricular
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dysfunction [11]. Despite promising data linking GDF-15
with poor outcomes in pulmonary vascular disorders, it
has not been measured in patients with ARDS. The
development of novel biomarkers may improve our
understanding of ARDS by identifying more accurate and
precise estimates of risk for poor outcomes in patients
with ARDS and elucidating underlying mechanisms that
drive these outcomes [12,13]. Biomarkers may also help
identify subgroups of patients that respond differently to
treatments. Studying therapies targeted to the subgroup
of patients who develop pulmonary vascular dysfunction
(PVD) in the setting of ARDS is difficult because pul-
monary artery catheters are no longer part of the routine
care in ARDS [14]. Therefore, a novel biomarker that is
easy to measure could identify and target therapies to
ARDS patients with PVD.
The Fluid and Catheter Treatment (FACT) Trial
enrolled patients with ARDS and demonstrated that
fluid management guided by a pulmonary artery catheter
(PAC) does not lead to an improvement in clinical out-
come when compared to fluid resuscitation guided by a
central venous catheter [14,15]. The 501 patients who
received a PAC as part of the study protocol now repre-
sent the largest available cohort of patients in which to
study PVD in ARDS. Given the strong association of
GDF-15 with poor outcomes in several diseases, we
sought to determine the association between GDF-15
levels and mortality as well as measures of extrapulmon-
ary organ failure in patients with ARDS. Furthermore,
given the need for a noninvasive biomarker of PVD in
patients with ARDS and the correlation of GDF-15 with
elevated right ventricular systolic pressure in patients
with scleroderma-associated pulmonary hypertension
[10], we sought to determine the utility of GDF-15 levels
in the identification of PVD in patients with ARDS
enrolled in the FACT Trial. We hypothesized that higher
GDF-15 levels would be associated with the presence of
PVD and with poor outcomes including mortality and
ventilator-free, ICU-free, and organ failure-free days.
Methods
We conducted a secondary analysis of patients enrolled
in the FACT Trial. Full inclusion and exclusion criteria
for the study are available as part of the parent manu-
script. Importantly, patients with severe chronic obstruc-
tive pulmonary disease or ‘clinically significant pulmonary
hypertension’ were excluded [14]. Patients were included
in this analysis if they were enrolled in the FACT Trial,
randomized to the pulmonary artery catheter (PAC) treat-
ment arm, and received a PAC. Patients were excluded if
they did not have sufficient PAC measurements to calcu-
late a pulmonary vascular resistance index (PVRi) and
transpulmonary gradient (TPG) or did not have a plasma
sample available.
Measurement of GDF-15
GDF-15 was quantified in the day 1 plasma samples
using the Human GDF-15 Quantikine ELISA Kit (R&D
Systems, Minneapolis, MN, USA Catalog No. DGD150),
following the manufacturer’s protocol. All samples were
obtained from the National Heart Lung and Blood Insti-
tute Biologic Specimen and Data Repository Information
Coordinating Center (BioLINCC). Samples were initially
diluted 4-fold with the Calibrator Diluent RD5-20
included in the kit, as recommended in the manufacturer’s
protocol. A subset of the plasma samples were out of the
range of detection, and were diluted up to 40-fold with the
Calibrator Diluent RD5-20 before requantification. GDF-
15 values were adjusted to account for the dilution factor.
ELISA plates were read on a VersaMax microplate reader
(Molecular Devices; Sunnyvale, CA, USA), using SoftMax
Pro v3.1.2 analysis software (MDS Analytical Technolo-
gies; Sunnyvale, CA, USA). Plates were read at 450nm,
with wavelength correction of 540 nm. All assays were
run in duplicate and results were averaged. In 92% of
the patients the value of both measurements was within
15% of the average.
Pulmonary vascular dysfunction
As previously described, we were unable to define PAH
by the traditional criteria of a mean pulmonary artery
pressure (mPAP) >25 mm Hg because 59% of the 500
patients with PACs in the FACT Trial had a pulmonary
arterial occlusion pressure (PAOP) >15 mm Hg [11].
Therefore, we used the PVRi and TPG to define PVD.
The PVRi is defined as: 80 × (mPAP-PAOP)/cardiac
index. Normal values for the PVRi are 255 - 285 dynes -
sec/cm-5/m2. We defined PVD as the presence of a
PVRi >285 dynes - sec/cm-5/m2 [16]. The TPG is calcu-
lated as: (PAP - mean PAOP) with PVD defined as a TPG
>12 mm Hg. All hemodynamic measurements were
obtained on study day 1 (the same study day that plasma
samples were collected).
Outcome variables
To analyze the association between GDF-15 levels and
outcome, we chose 60-day mortality as the primary out-
come variable. Secondary outcome variables included the
number of extrapulmonary organ failure-free days, the
number of ICU-free days, and the number of ventilator-
free days. Organ failure-free days were calculated using
the Brussels score, as previously described [17]. The
Brussels score places renal, coagulation, cardiovascular,
central nervous system, and hepatic failure into no organ
dysfunction, mild, moderate, severe, or extreme organ
dysfunction. Moderate, severe, or extreme organ dysfunc-
tion is considered to be clinically significant [17]. Patients
were categorized into the presence or absence of clini-
cally significant organ dysfunction for each study day.
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The number of days that the patient was alive without
organ failure through study day 28 was then calculated as
in prior ARDS Network studies [18-20]. To determine
the association between GDF-15 levels and the presence
of PVD, we used the presence of PVD as the outcome
variable, as defined above.
Statistical analysis
The Wilcoxon rank-sum test or Student’s t-test were
used to analyze differences in continuous variables
between patients with and without PVD. Simple linear
regression was used to test associations between contin-
uous variables. The chi-square test was used to test for
significant differences in categorical variables between
groups. To test the association between GDF-15 levels
and 60-day mortality, we initially performed logistic
regression using log-GDF-15 level as the predictor and
death at study day 60 as the outcome using the Hosmer-
Lemeshow statistic to ensure goodness of fit. To ease
interpretation, we then used quartiles of GDF-15 as the
predictor of interest with the first quartile as the control
group [4]. A priori, we included severity of illness mea-
sured by acute physiology and chronic health evaluation
(APACHE) III score in our models because our goal was
to test the ability of GDF-15 to predict outcomes. To test
for an association between GDF-15 levels and organ fail-
ure-free days, we constructed separate multiple linear
regression models using the log-GDF-15 quartile as the
predictor and ICU-free days, ventilator-free days, and
organ failure-free days as the outcome variable. A priori,
we also included APACHE III score as a covariate in this
model. We examined plots of residual versus predicted
values to ensure that assumptions of linear regressions
were met. Finally, to determine whether the association
between GDF-15 levels and mortality is independent of
other known predictors of poor outcomes in patients
with ARDS, we performed a post hoc multiple logistic
regression additionally adjusting for age, gender, race/
ethnicity, baseline creatinine, and ARDS risk factor.
To further describe whether GDF-15 levels significantly
add to APACHE III scores as a predictor of 60-day mor-
tality, we also constructed receiver operating characteristic
(ROC) curves with APACHE III alone and APACHE III
plus GDF-15 level, then calculated the difference in the c-
statistic. A c-statistic is commonly used to quantify the
capacity of a biomarker of interest to discriminate between
outcomes. Scores range from 0.5 to 1.0 with higher values
indicating a better predictive model. For binary outcomes,
the c-statistic is equivalent to the area under the ROC
curve. A difference of 0.05 in the c-statistic with and with-
out the biomarker of interest is generally considered to be
clinically significant [21]. To examine the association
between GDF-15 level and PVD, we constructed an ROC
curve using the log-GDF-15 level as the predictor and the
presence of PVD as the outcome.
Protection of human subjects
The institutional review boards of each participating
medical center or hospital approved the original FACT
Trial and patients or surrogates provided informed con-
sent prior to enrollment. The study was conducted in
accordance with the established ethical standards of the
medical centers and with the principles of the Declaration
of Helsinki. The ARDS Network provided de-identified
data for our analysis. Additional approval for this study
was obtained from the Colorado Multiple Institutional
Review Board (COMIRB Protocol No 10-0825).
Results
Of the 513 patients enrolled in the FACT Trial assigned
to the PAC arm, 501 received a PA catheter. Of those
that received a PAC, 400 patients were eligible for inclu-
sion in this analysis (Figure 1). The most common reason
that patients were excluded was the lack of an available
day 1 measurement of PVRi or TPG (n = 57). There was
no significant difference in age, 60-day mortality, severity
of illness, or ventilator-free days between the patients
who were excluded and the patients who were included
in this study. PVD was present in 187 (47%) of the 400
patients when assessed using PVRi and 236 (59%) of the
400 patients when assessed using TPG. The overall
60-day mortality in the cohort was 26.5%. On average,
patients who died were older, more likely to have sepsis
as an ARDS risk factor, be immunosuppressed, and have
higher APACHE III scores, baseline creatinine, and a
lower PaO2/FiO2 ratio (Table 1). The median plasma
GDF-15 level was 6,167 pg/mL (interquartile range (IQR)
3,585 pg/mL, 10,150 pg/mL) with a range of 880 pg/mL
to 23,830 pg/mL. Only three of the 400 patients (0.7%)
1001 randomized in the 
FACT Trial 
501 received a PAC 
488 not assigned to PAC 
 12 did not receive PAC 
57 unable to measure    
PVRi/TPG 
44 no day 1 plasma sample 
400 patients in current 
sample 
Figure 1 Selection of patients for inclusion in this analysis.
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had GDF-15 levels under 1,200 pg/mL, the commonly
accepted cutoff for normal values [4].
GDF-15 level and mortality
Patients whose GDF-15 level was in the third or fourth
quartile had a significantly higher 60-day mortality rate
when compared to patients whose GDF-15 level was in
the first quartile (Figure 2). The c-statistic for log-GDF-15
alone as a predictor of mortality was 0.72 while the
c-statistic for APACHE III alone as a predictor of mor-
tality was also 0.72. At an optimal cutoff of 8,103 pg/mL,
the sensitivity and specificity of GDF-15 for predicting
60-day mortality were 62% (95% CI 53%, 71%) and 76%
(95% CI 71%, 81%), respectively. When log-GDF-15 levels
were added to APACHE III score as a predictor of 60-day
mortality, the c-statistic for the ROC curve increased from
0.72 to 0.77 (Figure 3). Adjusting for severity of illness
measured by APACHE III score, the odds of death at
60 days increased 2.43 times per log increase in GDF-15
(95% CI 1.65, 3.64; P <0.001). After adjusting for severity
of illness measured by APACHE III score, patients whose
GDF-15 level was in the highest quartile had a significantly
higher odds of death when compared to patients whose
GDF-15 level was in the first quartile (Table 2).
In a multiple logistic regression model additionally
adjusted for age, gender, race/ethnicity, baseline serum
creatinine, and ARDS risk factor, the odds of death were
increased 2.86 times per log increase in GDF-15 (95%
CI 1.84, 4.54; P <0.001). In a multiple logistic regression
Table 1 Baseline characteristics of patients included in
this analysis.







Age 47 [37,57] 51 [40,65] 0.01
Gender (% male) 51 57 0.35
Race (%) 0.04
White 70 55
African American 20 30
Hispanic 7 9
Other 3 6
ARDS risk factor (%)
Sepsis 38 53 0.01
Aspiration 22 18 0.33
Pneumonia 64 67 0.62
Trauma 10 5 0.10
Other 9 6 0.30
Comorbidities (%)
Diabetes mellitus 18 16 0.27
Cirrhosis 4 3 0.62
Immunosuppression 6 17 <0.01
APACHE III score 86 [67,106] 111 [91,132] <0.01
Creatinine (mg/dL) 0.9 [0.7, 1.4] 1.3 [0.9, 1.9] <0.01









Continuous variables are presented as median [interquartile range].
Figure 2 Higher levels of growth differentiation factor-15 are
associated with a higher 60-day mortality. *P <0.001 when
compared to quartile 1. n = 100 in each quartile.
Figure 3 Receiver operating characteristic curves for the prediction of 60-day mortality.
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model adjusting for the same covariates, the association
between GDF-15 in the second and third quartiles were
unchanged while the odds of death for patients in the
fourth quartile of GDF-15 was 5.26 times that of patients
in the first quartile (95% CI 2.31, 12.67; P <0.001).
GDF-15 level and secondary outcomes
In a univariate analysis, patients with GDF-15 levels in
the fourth quartile had significantly few ventilator-free and
ICU-free days when compared to patients with GDF-15
levels in the first quartile (Table 3). Similarly, patients with
GDF-15 levels in the fourth quartile had fewer cardiovas-
cular, central nervous system (CNS), coagulation, renal,
and hepatic failure-free days when compared to patients
with GDF-15 levels in the first quartile. After adjusting for
severity of illness measured by APACHE III scores,
patients with GDF-15 levels in the third and fourth quar-
tile had significantly fewer ICU-free and ventilator-free
days when compared to patients with GDF-15 levels in the
first quartile (Table 4). After adjusting for severity of
illness, patients whose GDF-15 levels were in the third and
fourth quartiles had significantly fewer cardiovascular,
CNS, coagulation, renal, and hepatic failure-free days
when compared to patients in the first quartile (Table 4).
GDF-15 level as a predictor of pulmonary vascular
dysfunction
On average, for each log increase in GDF-15, PVRi
increased by 41.2 dynes - sec/cm-5/m2 (95% CI 17.3,
66.2 dynes - sec/cm-5/m2; r = 0.17; P <0.001). Similarly, for
each log increase in GDF-15, TPG increased by an average
of 1.33 mm Hg (95% CI 0.45, 2.20 mm Hg; r = 0.15;
P = 0.003). However, there was no significant difference in
the median level of GDF-15 in patients with PVD when
compared to patients without PVD (P = 0.05, Figure 4).
In a multiple logistic regression model adjusting for age,
PaO2 to FiO2 ratio, creatinine, and APACHE III score,
there was no significant association between the level of
GDF-15 and the presence of PVD (adjusted OR 1.21
per log increase in GDF-15; 95% CI 0.86, 1.70; P = 0.27).
Table 2 Adjusted odds ratios for GDF-15 quartile as a
predictor of 60-day mortality.
Adjusted OR* 95% CI P value
1st quartile Reference – –
2nd quartile 1.20 0.53, 2.78 0.67
3rd quartile 2.02 0.95, 4.52 0.07
4th quartile 4.28 2.05, 9.42 <0.001
*Adjusted for severity of illness measured by acute physiology and chronic
health evaluation (APACHE) III score.
Table 3 Ventilator-free, ICU-free, and specific organ















19 [2,23] 12 0[23] 2 0[20] <0.001
ICU-free days 20
[13,23]


































Data are presented as median [interquartile range].
Table 4 Results of separate multiple linear regression models with ventilator-free days, ICU-free days, and specific
organ failure-free days as the outcome variables and GDF-15 quartile as the predictor variable.
Quartile 2 Quartile 3 Quartile 4
b* 95% CI P value b * 95% CI P value b * 95% CI P value




<0.01 -6.56 -9.38, -3.74 <0.01
ICU-free days -1.88 -4.39, 0.62 0.14 -5.25 -7.81,
-2.71
<0.01 -6.25 -8.87, -3.63 <0.01
Organ failure-free days
Cardiovascular -0.85 -3.32, 1.61 0.50 -2.38 -4.87, 0.12 0.06 -6.03 -8.61, -3.45 <0.01















Hepatic -0.01 -2.42, 2.41 0.99 -2.52 -4.96, -0.07 0.04 -8.49 -11.02,
-5.97
< 0.01
Patients in GDF-15 quartile 1 served as the control group and, therefore, are not included in the table. *Parameter estimates shown are the difference when
compared to patients in GDF-15 quartile 1 after adjusting for APACHE III score. CNS, central nervous system; 95% CI, 95% confidence interval.
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A ROC curve with log-GDF-15 level as the predictor and
the presence of PVD as the outcome variable yielded a
c-statistic of 0.56. At an optimal cutoff of 5,105 ng/dL,
GDF-15 had a sensitivity of 65% (95% CI 58%, 72%) and a
specificity of 46% (95% CI 40%, 53%) for the identification
of PVD.
Discussion
In this large cohort of patients with invasive hemody-
namic measurements used to define the presence of
PVD, we demonstrated a dose-dependent and significant
association between plasma GDF-15 levels and mortality
in addition to several secondary outcomes in patients
with ARDS. Of note, only three (0.7%) patients in this
study had a GDF-15 level that was less than 1,200 ng/L,
the commonly accepted cutoff for normal. In contrast,
we demonstrated that, although plasma GDF-15 levels
are associated with higher measurements of TPG and
PVRi, there is significant variability in GDF-15 levels
between patients with and without PVD. Thus, the sen-
sitivity and specificity of GDF-15 as a single test for the
identification of PVD are poor and plasma GDF-15
should not be used as a single biomarker for the identi-
fication of PVD in this population. We highlight that we
chose to use TPG and PVRi to define PVD so that
patients with an elevated PAOP would not be classified
as having PVD.
Although many of the effects of GDF-15 remain
unknown, recent work has begun to elucidate its role in
acute coronary syndromes. In a series of experiments
following coronary artery ligation in mice, Kempf and
colleagues demonstrate that GDF-15 inhibits polymor-
phonuclear leukocyte recruitment by interfering with
chemokine signaling and activation of integrins [8].
Because PMN recruitment and activation play a vital
role in ARDS, it is possible that higher GDF-15 levels
are expressed in an effort to attenuate this response
[22]. Other biomarkers that are associated with poor
outcomes have mechanisms that should be beneficial.
For example, brain natriuretic peptide (BNP) has a sym-
pathoinhibitory effect in patients with congestive heart
failure [23]. However, higher plasma levels of BNP are a
poor prognostic indicator in congestive heart failure
[24-27]. A limitation of our study is that we did not
measure proinflammatory cytokines. In the absence of
this information, and without a more definitive under-
standing of the effects of GDF-15, it is not clear what
mediates the association between GDF-15 and poor out-
comes. GDF-15 may impair neutrophil recruitment and
chemokine signaling thus leading to deleterious effects
in ARDS. However, future basic, translational or clinical
work would be necessary to determine whether GDF-15
mediates poor outcomes in ARDS.
In prior studies, several biomarkers have been asso-
ciated with mortality in patients with ARDS including
surfactant protein D [28], interleukin-8 [29], soluble
tumor necrosis factor receptor-1 [30], von Willebrand
factor [31], and soluble intracellular adhesion molecule-
1 [32]. When combined into a panel, these biomarkers
significantly improve risk prediction by APACHE III
alone, increasing the area under the curve (AUC) from
0.680 to 0.747 in the derivation cohort and from 0.767
to 0.793 in a validation cohort [12]. It is of interest that
GDF-15 alone increased the AUC by 0.05 in our study.
However, it is not clear how GDF-15 would perform in
a validation cohort. Furthermore, we cannot draw any
conclusions regarding the performance of GDF-15 rela-
tive to other prognostic biomarkers in ARDS.
As highlighted in discussions by Ware, Calfee and col-
leagues [12,13], there are at least two important reasons to
refine the ability to provide a precise prognosis for patients
with ARDS. First, in large randomized controlled trials, the
mortality in control groups has declined over time. In the
three most recent ARDS network studies, mortality in the
control group ranged from 16 to 23% [33-35]. While this
may be due to important advancements in the care of
patients with ARDS, it creates significant logistical chal-
lenges for the conduct of future treatment trials. Specifi-
cally, absent treatments that demonstrate a dramatic
improvement in mortality, randomized controlled trials
that have sufficient power to demonstrate a difference in
outcomes may be cost prohibitive. Therefore, the ability to
select a population with a higher mortality but who may
still benefit from treatment may become more imperative.
The ability to do this with the greatest precision offers the
opportunity to advance clinical research in ARDS through
the cost-efficient conduct of treatment trials.
Second, future therapies for ARDS may have signifi-
cant undesired side effects that place patients at addi-
tional risk for poor outcomes. In that case, the ability to
develop an accurate and precise estimate of mortality
Figure 4 The median (horizontal lines), interquartile range
(box), and range (vertical lines) of GDF-15 levels in patients
with and without pulmonary vascular dysfunction (PVD).
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for a given patient may help weigh the risks and benefits
of a treatment and, therefore, identify patients most
likely to derive an overall benefit. Such an approach has
been used to treat acute coronary syndromes in the
form of the Thrombolysis in Myocardial Infarction
(TIMI) risk score. Of note, GDF-15 may provide prog-
nostic information above and beyond the information
provided by the TIMI risk score highlighting its ability
to independently improve mortality prediction for other
patient populations [2].
There are important limitations to this study. First,
although the plasma samples were obtained on the same
study day as the invasive hemodynamic measurements
used to calculate the PVRi, the half-life of GDF-15 is
only 20 minutes. The timing of plasma collection rela-
tive to hemodynamic measurements was not collected
in the FACT Trial. Therefore, the utility of GDF-15 as a
biomarker for the identification of PVD in patients with
ARDS may have been obscured in our study. Further-
more, because GDF-15 measurements were obtained at
a single point in time, we cannot make inferences
regarding GDF-15 levels later in the course of disease.
For example, persistently elevated GDF-15 levels may be
more strongly correlated with poor outcomes. Second,
we did not validate GDF-15 as a predictor of outcomes
in ARDS in a separate cohort. This would be necessary
before drawing any conclusions regarding the clinical
utility of GDF-15 as a predictor of outcomes in patients
with ARDS. Third, the patients in this cohort were
enrolled in a randomized controlled trial. Thus, there
could be a selection bias that could limit the ability to
generalize our findings to patients with ARDS in gen-
eral. Finally, nearly all of the patients included in this
analysis had moderate ARDS by Berlin criteria [36].
Therefore, our findings may not apply to patients with
mild or severe ARDS.
Conclusion
In patients with ARDS enrolled in the FACT Trial who
received a PAC, we demonstrated that higher plasma
GDF-15 levels are associated with an increased mortality
and fewer ventilator-free, ICU-free, and organ failure-
free days. Further studies are needed to understand how
GDF-15 performs as a risk predictor in a separate
cohort and to understand how GDF-15 performs relative
to other known biomarkers for poor outcomes in
patients with ARDS.
Key messages
• Higher levels of growth differentiation factor-15
are associated with poor outcomes in patients with
ARDS including a higher odds of death at 60 days,
fewer ICU-free and ventilator-free days, and fewer
organ failure-free days.
• Although GDF-15 levels are associated with trans-
pulmonary gradient and pulmonary vascular resis-
tance index, GDF-15 was not useful as a single
biomarker for the identification of PVD in patients
with ARDS.
• The timing of GDF-15 measurements relative to
hemodynamic measurements in this study is not
known. Thus, GDF-15 levels may be better at identi-
fying the presence of PVD than we report.
• Future studies are needed to validate the usefulness
of GDF-15 as a prognostic biomarker and to com-
pare its utility relative to other known biomarkers in
patients with ARDS.
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